Johnson & Johnson Net Profit Margin 2012-2026 | JNJ
Current and historical net profit margin for Johnson & Johnson (JNJ) from 2012 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue. Johnson & Johnson net profit margin for the three months ending March 31, 2026 was .
| Johnson & Johnson Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-03-31 | $96.36B | $21.04B | 21.83% |
| 2025-12-31 | $94.19B | $26.80B | 28.46% |
| 2025-09-30 | $92.15B | $25.12B | 27.26% |
| 2025-06-30 | $90.63B | $22.66B | 25.00% |
| 2025-03-31 | $89.33B | $21.81B | 24.41% |
| 2024-12-31 | $88.82B | $14.07B | 15.84% |
| 2024-09-30 | $87.70B | $14.68B | 16.74% |
| 2024-06-30 | $86.58B | $38.02B | 43.91% |
| 2024-03-31 | $85.65B | $38.48B | 44.92% |
| 2023-12-31 | $85.16B | $35.15B | 41.28% |
| 2023-09-30 | $76.31B | $34.62B | 45.37% |
| 2023-06-30 | $74.96B | $13.05B | 17.42% |
| 2023-03-31 | $77.46B | $12.72B | 16.43% |
| 2022-12-31 | $79.99B | $17.94B | 22.43% |
| 2022-09-30 | $77.21B | $19.16B | 24.81% |
| 2022-06-30 | $80.55B | $18.37B | 22.80% |
| 2022-03-31 | $79.85B | $19.83B | 24.84% |
| 2021-12-31 | $78.74B | $20.88B | 26.52% |
| 2021-09-30 | $91.45B | $17.88B | 19.55% |
| 2021-06-30 | $89.19B | $17.77B | 19.92% |
| 2021-03-31 | $84.21B | $15.12B | 17.95% |
| 2020-12-31 | $82.58B | $14.71B | 17.82% |
| 2020-09-30 | $80.86B | $16.99B | 21.01% |
| 2020-06-30 | $80.50B | $15.19B | 18.86% |
| 2020-03-31 | $82.73B | $17.17B | 20.75% |
| 2019-12-31 | $82.06B | $15.12B | 18.42% |
| 2019-09-30 | $81.71B | $14.15B | 17.32% |
| 2019-06-30 | $81.33B | $16.33B | 20.08% |
| 2019-03-31 | $81.59B | $14.68B | 17.99% |
| 2018-12-31 | $81.58B | $15.30B | 18.75% |
| 2018-09-30 | $81.38B | $1.54B | 1.89% |
| 2018-06-30 | $80.68B | $1.37B | 1.70% |
| 2018-03-31 | $78.69B | $1.25B | 1.58% |
| 2017-12-31 | $76.45B | $1.30B | 1.70% |
| 2017-09-30 | $74.36B | $15.83B | 21.28% |
| 2017-06-30 | $72.53B | $16.34B | 22.52% |
| 2017-03-31 | $72.17B | $16.51B | 22.87% |
| 2016-12-31 | $71.89B | $16.54B | 23.01% |
| 2016-09-30 | $71.60B | $15.94B | 22.27% |
| 2016-06-30 | $70.88B | $15.03B | 21.20% |
| 2016-03-31 | $70.18B | $15.55B | 22.15% |
| 2015-12-31 | $70.07B | $15.41B | 21.99% |
| 2015-09-30 | $70.52B | $14.72B | 20.87% |
| 2015-06-30 | $71.88B | $16.11B | 22.41% |
| 2015-03-31 | $73.59B | $15.92B | 21.63% |
| 2014-12-31 | $74.33B | $16.32B | 21.96% |
| 2014-09-30 | $74.43B | $17.32B | 23.27% |
| 2014-06-30 | $73.54B | $15.55B | 21.15% |
| 2014-03-31 | $71.92B | $15.06B | 20.94% |
| 2013-12-31 | $71.31B | $13.83B | 19.40% |
| 2013-09-30 | $70.52B | $12.88B | 18.26% |
| 2013-06-30 | $69.99B | $12.87B | 18.38% |
| 2013-03-31 | $68.59B | $10.44B | 15.22% |
| 2012-12-31 | $67.22B | $10.85B | 16.14% |
| 2012-09-30 | $65.92B | $8.50B | 12.90% |
| 2012-06-30 | $64.87B | $8.74B | 13.47% |
| 2012-03-31 | $65.00B | $10.11B | 15.55% |
| 2011-12-31 | $65.03B | $9.67B | 14.87% |
| 2011-09-30 | $64.42B | $11.40B | 17.69% |
| 2011-06-30 | $63.40B | $11.61B | 18.32% |
| 2011-03-31 | $62.13B | $12.28B | 19.77% |
| 2010-12-31 | $61.59B | $13.33B | 21.65% |
| 2010-09-30 | $62.49B | $13.60B | 21.76% |
| 2010-06-30 | $62.59B | $13.53B | 21.61% |
| 2010-03-31 | $62.50B | $13.29B | 21.26% |
| 2009-12-31 | $61.90B | $12.27B | 19.82% |
| 2009-09-30 | $60.53B | $12.77B | 21.10% |
| 2009-06-30 | $61.37B | $12.74B | 20.76% |
| 2009-03-31 | $62.58B | $12.86B | 20.55% |
| 2008-12-31 | $63.75B | $12.95B | 20.31% |
| 2008-09-30 | $64.52B | $12.61B | 19.54% |
| 2008-06-30 | $63.57B | $11.85B | 18.64% |
| 2008-03-31 | $62.25B | $11.60B | 18.64% |
| 2007-12-31 | $61.10B | $10.58B | 17.31% |
| 2007-09-30 | $58.82B | $10.37B | 17.63% |
| 2007-06-30 | $57.14B | $10.58B | 18.52% |
| 2007-03-31 | $55.37B | $10.32B | 18.64% |
| 2006-12-31 | $53.32B | $11.05B | 20.73% |
| 2006-09-30 | $52.25B | $10.98B | 21.01% |
| 2006-06-30 | $51.28B | $10.76B | 20.98% |
| 2006-03-31 | $50.67B | $10.53B | 20.77% |
| 2005-12-31 | $50.51B | $10.06B | 19.92% |
| 2005-09-30 | $50.66B | $8.85B | 17.48% |
| 2005-06-30 | $49.90B | $8.66B | 17.35% |
| 2005-03-31 | $48.62B | $8.53B | 17.54% |
| 2004-12-31 | $47.35B | $8.18B | 17.28% |
| 2004-09-30 | $45.85B | $9.14B | 19.93% |
| 2004-06-30 | $44.75B | $8.87B | 19.82% |
| 2004-03-31 | $43.60B | $7.62B | 17.48% |
| 2003-12-31 | $41.86B | $7.20B | 17.19% |
| 2003-09-30 | $40.01B | $6.74B | 16.84% |
| 2003-06-30 | $38.64B | $6.39B | 16.54% |
| 2003-03-31 | $37.38B | $6.83B | 18.28% |
| 2002-12-31 | $36.30B | $6.60B | 18.17% |
| 2002-09-30 | $35.12B | $6.32B | 17.99% |
| 2002-06-30 | $34.10B | $6.12B | 17.95% |
| 2002-03-31 | $33.21B | $5.95B | 17.92% |
| 2001-12-31 | $32.32B | $5.67B | 17.54% |
| 2001-09-30 | $31.20B | $5.45B | 17.48% |
| 2001-06-30 | $30.58B | $5.25B | 17.16% |
| 2001-03-31 | $30.07B | $5.13B | 17.06% |
| 2000-12-31 | $29.54B | $4.89B | 16.56% |
| 2000-09-30 | $29.30B | $4.75B | 16.22% |
| 2000-06-30 | $28.75B | $4.54B | 15.80% |
| 2000-03-31 | $28.05B | $4.34B | 15.48% |
| 1999-12-31 | $27.47B | $4.17B | 15.17% |
| 1999-09-30 | $27.06B | $3.52B | 12.99% |
| 1999-06-30 | $25.99B | $3.37B | 12.96% |
| 1999-03-31 | $24.89B | $3.22B | 12.94% |
| 1998-12-31 | $24.00B | $3.00B | 12.52% |
| 1998-09-30 | $23.16B | $3.53B | 15.25% |
| 1998-06-30 | $22.93B | $3.42B | 14.92% |
| 1998-03-31 | $22.75B | $3.31B | 14.56% |
| 1997-12-31 | $22.63B | $3.30B | 14.60% |
| 1997-09-30 | $22.50B | $3.23B | 14.35% |
| 1997-06-30 | $22.32B | $3.12B | 14.00% |
| 1997-03-31 | $22.00B | $3.01B | 13.66% |
| 1996-12-31 | $21.62B | $2.89B | 13.35% |
| 1996-09-30 | $20.96B | $2.80B | 13.34% |
| 1996-06-30 | $20.30B | $2.67B | 13.15% |
| 1996-03-31 | $19.68B | $2.54B | 12.90% |
| 1995-12-31 | $18.84B | $2.40B | 12.75% |
| 1995-09-30 | $18.09B | $2.32B | 12.81% |
| 1995-06-30 | $17.39B | $2.22B | 12.76% |
| 1995-03-31 | $16.54B | $2.12B | 12.79% |
| 1994-12-31 | $14.97B | $2.01B | 13.40% |
| 1994-09-30 | $14.41B | $1.96B | 13.62% |
| 1994-06-30 | $13.88B | $1.89B | 13.63% |
| 1994-03-31 | $13.51B | $1.83B | 13.53% |
| 1993-12-31 | $14.14B | $1.79B | 12.64% |
| 1993-09-30 | $14.11B | $1.76B | 12.47% |
| 1993-06-30 | $14.08B | $1.72B | 12.21% |
| 1993-03-31 | $13.96B | $1.68B | 12.01% |
| 1992-12-31 | $13.75B | $1.65B | 11.99% |
| 1992-09-30 | $13.40B | $1.62B | 12.06% |
| 1992-06-30 | $13.04B | $1.57B | 12.00% |
| 1992-03-31 | $12.66B | $1.52B | 12.00% |
| 1991-12-31 | $12.45B | $1.46B | 11.74% |
| 1991-09-30 | $12.00B | $1.42B | 11.83% |
| 1991-06-30 | $11.75B | $1.37B | 11.66% |
| 1991-03-31 | $11.54B | $1.32B | 11.41% |
| 1990-12-31 | $11.23B | $1.14B | 10.18% |
| 1990-09-30 | $11.00B | $1.11B | 10.12% |
| 1990-06-30 | $10.59B | $1.07B | 10.06% |
| 1990-03-31 | $10.15B | $1.01B | 9.94% |
| 1989-12-31 | $9.76B | $1.08B | 11.09% |
| 1989-09-30 | $9.49B | $1.06B | 11.21% |
| 1989-06-30 | $9.23B | $1.04B | 11.24% |
| 1989-03-31 | $9.13B | $1.01B | 11.08% |
| 1988-12-31 | $9.00B | $0.97B | 10.82% |
| 1988-09-30 | $8.73B | $0.95B | 10.91% |
| 1988-06-30 | $8.57B | $0.92B | 10.77% |
| 1988-03-31 | $8.34B | $0.88B | 10.50% |
| 1987-12-31 | $8.01B | $0.83B | 10.40% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |